ArticleInternational journal of clinical oncology2025
The prognostic factors and treatment patterns of the first recurrence of retroperitoneal liposarcoma.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to identify prognostic factors and treatment patterns at the first recurrence of retroperitoneal liposarcoma (LPS).
methodsMedical records of 150 patients who underwent resection for primary retroperitoneal LPS were reviewed. Of the 94 patients with local or distant recurrence, prognostic factors and treatment approaches were retrospectively analyzed.
resultsAt recurrence, 41 patients underwent surgery, 12 received radiation, 23 received chemotherapy, 12 were under active surveillance, and 6 received best supportive care. In univariate analysis, well-differentiated primary tumors predicted better overall survival (OS) compared to dedifferentiated tumors (p = 0.004). Conversely, shorter recurrence-free survival (RFS) after initial surgery, smaller recurrent tumors at treatment, and high neutrophil-to-lymphocyte ratio (NLR) at recurrence were associated with poorer OS (p = 0.0418, 0.007, and 0.0475, respectively). Treatment decisions were influenced by RFS, time from recurrence to treatment, initial tumor differentiation, recurrence site, and multiplicity. Among those who had surgery for recurrence, 29.2% (12/41) showed a change in tumor differentiation. RFS was a significant predictor of this change (p = 0.026). Additionally, NLR at recurrence and the waiting period from recurrence to treatment were significant prognostic factors in surgically treated patients (p = 0.005 and 0.028, respectively).
conclusionsRFS, timing of treatment, initial tumor differentiation, and recurrence characteristics influence treatment choices at first recurrence. RFS may predict changes in tumor differentiation, while NLR at recurrence and the waiting period from recurrence to treatment are important prognostic indicators in patients undergoing surgery.
Indexed as
Identifiers
40434510What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.